We are live on ! Find out more
DRUG

Bright Minds Biosciences
DRUG

14 hedge funds and large institutions have $509K invested in Bright Minds Biosciences in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

40% more funds holding

Funds holding: 10 → 14 (+4)

28% more capital invested

Capital invested by funds: $399K → $509K (+$110K)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.15% less ownership

Funds ownership: 0.82% → 0.67% (-0.15%)

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JMPWA
JP Morgan Private Wealth Advisors
California
+$14.7K
2
Two Sigma Investments
Two Sigma Investments
New York
+$14.4K
3
Bank of America
Bank of America
North Carolina
+$13.8K
4
TSS
Two Sigma Securities
New York
+$13.2K
5
UBS Group
UBS Group
Switzerland
+$9.8K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$86K
2
BFM
Boothbay Fund Management
New York
-$9K
3
Jane Street
Jane Street
New York
-$6.97K
4
AI
AdvisorShares Investments
Maryland
-$5.57K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
AdvisorShares Investments
Maryland
$351K -$5.57K -859 -1%
QFA
2
Quattro Financial Advisors
Texas
$26K – – –
Jane Street
3
Jane Street
New York
$24K -$6.97K -1,075 -22%
UBS Group
4
UBS Group
Switzerland
$18K +$9.8K +1,512 +104%
CCA
5
Checchi Capital Advisers
California
$17K – – –
BlackRock
6
BlackRock
New York
$15K – – –
Two Sigma Investments
7
Two Sigma Investments
New York
$14K +$14.4K +2,214 New
JMPWA
8
JP Morgan Private Wealth Advisors
California
$14K +$14.7K +2,266 New
TSS
9
Two Sigma Securities
New York
$13K +$13.2K +2,041 New
Bank of America
10
Bank of America
North Carolina
$13K +$13.8K +2,131 New
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$2K +$19 +3 +0.9%
APC
12
Aspire Private Capital
North Carolina
$1K – – –
TRCT
13
Tower Research Capital (TRC)
New York
$1K +$817 +126 New
IC
14
Ikarian Capital
Texas
– -$86K -21,192 Closed
BFM
15
Boothbay Fund Management
New York
– -$9K -2,208 Closed
Osaic Holdings
16
Osaic Holdings
Arizona
– +$519 +80 New

DRUG Hedge Fund Activity: Q3 2022 in Review

14 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q3 2022, worth a combined $509K — up 28% from $399K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new DRUG positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was JP Morgan Private Wealth Advisors, opening a new position worth an estimated $14.7K. The largest seller was Ikarian Capital, exiting entirely with an estimated $86K sold.

  • 14 institutional investors held Bright Minds Biosciences (DRUG) as of Q3 2022, up from 10 in Q2 2022.
  • Funds reported $509K of Bright Minds Biosciences stock for Q3 2022, up 28% quarter-over-quarter.
  • 6 funds opened new Bright Minds Biosciences positions in Q3 2022 and 2 closed out, a net change of +4 holders.
  • The largest Bright Minds Biosciences buyer in Q3 2022 was JP Morgan Private Wealth Advisors, an estimated $14.7K added.
  • The largest Bright Minds Biosciences seller in Q3 2022 was Ikarian Capital, an estimated $86K sold.

Based on aggregated 13F filings for Q3 2022.